Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse 04:00:44 2024-05-22 pm EDT Pre-market 08:34:09 am
29.6 USD +3.64% Intraday chart for Pfizer, Inc. 29.62 +0.05%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Asymchem Laboratories Buys Pfizer's Former UK Site; Hong Kong Shares Slide 3% MT
News Highlights : Top Company News of the Day - Thursday at 3 AM ET DJ
News Highlights : Top Company News of the Day - Thursday at 1 AM ET DJ
News Highlights : Top Company News of the Day - Wednesday at 11 PM ET DJ
News Highlights : Top Company News of the Day - Wednesday at 9 PM ET DJ
Health Care Up as Vaccine Makers Gain - Health Care Roundup DJ
US IS IN 'ACTIVE CONVERSATIONS' WITH MRNA VACCINE MAKERS PFIZER… RE
Sector Update: Health Care Stocks Slightly Higher Late Afternoon MT
Sector Update: Health Care MT
Pfizer to Cut Costs in Multi-Year Effort -- Update DJ
Pfizer Looks for $1.5 Billion in Savings by 2027, Expects One-Time Cost Reduction Charge of $1.7 Billion MT
Pfizer to Cut Costs in Multi-Year Effort DJ
Pfizer targets $1.5 bln in savings by 2027 as it streamlines operations RE
Pfizer launches multi-year cost-cuts program, eyes $1.5 bln in savings RE
Pfizer: RSV vaccine launched in Canada CF
Sector Update: Health Care Stocks Advance Late Afternoon MT
China-Based Asymchem Laboratories Will Operate Former Pfizer Manufacturing Facility in UK DJ
Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon MT
Sector Update: Health Care MT
Senate Finance Committee Chairman Questions Pfizer's Tax Practices MT
Global markets live: Apple, Tesla, Pfizer, AstraZeneca, Microsoft... Our Logo
DA Davidson Raises Price Target on Pfizer to $35 From $30, Maintains Buy/Add Rating MT
Correction: AstraZeneca Ordered to Pay $108 Million to Pfizer for Patent Violations MT
AstraZeneca Ordered to Pay $108 Million to Pfizer for Patent Violations MT
Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial RE
Chart Pfizer, Inc.
More charts
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
29.6 USD
Average target price
31.94 USD
Spread / Average Target
+7.90%
Consensus
  1. Stock Market
  2. Equities
  3. PFE Stock
  4. News Pfizer, Inc.
  5. Pfizer to Settle More Than 10,000 Zantac Cancer Lawsuits